Vanguard Group’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-38,687
| Closed | -$115K | – | 4598 |
|
|
2023
Q3 | $115K | Hold |
38,687
| – | – | ﹤0.01% | 4332 |
|
|
2023
Q2 | $94K | Hold |
38,687
| – | – | ﹤0.01% | 4397 |
|
|
2023
Q1 | $65.8K | Buy |
38,687
+28,644
| +285% | +$64.9K | ﹤0.01% | 4443 |
|
|
2022
Q4 | $17.6K | Sell |
10,043
-72,455
| -88% | -$176K | ﹤0.01% | 4498 |
|
|
2022
Q3 | $495K | Buy |
82,498
+59,043
| +252% | +$495K | ﹤0.01% | 4209 |
|
|
2022
Q2 | $369K | Hold |
23,455
| – | – | ﹤0.01% | 4364 |
|
|
2022
Q1 | $452K | Hold |
23,455
| – | – | ﹤0.01% | 4421 |
|
|
2021
Q4 | $446K | Buy |
23,455
+841
| +4% | +$23.8K | ﹤0.01% | 4448 |
|
|
2021
Q3 | $1.03M | Buy |
22,614
+2,667
| +13% | +$131K | ﹤0.01% | 4239 |
|
|
2021
Q2 | $1.22M | Buy |
19,947
+18,206
| +1,046% | +$1.28M | ﹤0.01% | 4114 |
|
|
2021
Q1 | $177K | Buy |
+1,741
| New | +$150K | ﹤0.01% | 4278 |
|
|
2020
Q2 | – | Sell |
-125
| Closed | -$23K | – | 4108 |
|
|
2020
Q1 | $23K | Hold |
125
| – | – | ﹤0.01% | 4042 |
|
|
2019
Q4 | $32K | Hold |
125
| – | – | ﹤0.01% | 4067 |
|
|
2019
Q3 | $25K | Sell |
125
-5
| -4% | -$1.2K | ﹤0.01% | 4122 |
|
|
2019
Q2 | $47K | Sell |
130
-376
| -74% | -$293K | ﹤0.01% | 4116 |
|
|
2019
Q1 | $669K | Buy |
506
+84
| +20% | +$136K | ﹤0.01% | 3722 |
|
|
2018
Q4 | $683K | Buy |
422
+82
| +24% | +$194K | ﹤0.01% | 3667 |
|
|
2018
Q3 | $970K | Hold |
340
| – | – | ﹤0.01% | 3729 |
|
|
2018
Q2 | $1.13M | Sell |
340
-27
| -7% | -$91.1K | ﹤0.01% | 3653 |
|
|
2018
Q1 | $1.27M | Buy |
367
+237
| +182% | +$703K | ﹤0.01% | 3596 |
|
|
2017
Q4 | $215K | Hold |
130
| – | – | ﹤0.01% | 3921 |
|
|
2017
Q3 | $560K | Buy |
130
+1
| +0.8% | +$5.14K | ﹤0.01% | 3724 |
|
|
2017
Q2 | $927K | Buy |
129
+99
| +330% | +$862K | ﹤0.01% | 3583 |
|
|
2017
Q1 | $230K | Buy |
30
+12
| +67% | +$83.1K | ﹤0.01% | 3884 |
|
|
2016
Q4 | $100K | Buy |
18
+8
| +80% | +$40.9K | ﹤0.01% | 3973 |
|
|
2016
Q3 | $87K | Hold |
10
| – | – | ﹤0.01% | 3994 |
|
|
2016
Q2 | $100K | Hold |
10
| – | – | ﹤0.01% | 4027 |
|
|
2016
Q1 | $168K | Buy |
10
+7
| +233% | +$159K | ﹤0.01% | 3974 |
|
|
2015
Q4 | $78K | Buy |
+3
| New | +$56.7K | ﹤0.01% | 4103 |
|
Vanguard Group's TMBR Position: Q4 2023 in Review
Vanguard Group sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q4 2023, closing a stake of 38,687 shares — an estimated $115K sold.
Vanguard Group first reported a position in TMBR in Q4 2015 and held it in 29 quarters. The position peaked at $1.27M in Q1 2018. 0 funds tracked by Wall St. Rank hold TMBR as of Q4 2023.
- Vanguard Group reported no remaining Timber Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Vanguard Group sold 38,687 Timber Pharmaceuticals, Inc. shares in Q4 2023, an estimated $115K.
- Vanguard Group first reported a position in Timber Pharmaceuticals, Inc. in Q4 2015 and held it in 29 quarters.
- Vanguard Group's Timber Pharmaceuticals, Inc. position peaked at $1.27M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q4 2023.
Based on Vanguard Group's 13F filing for Q4 2023, filed 14 Feb 2024.